34
Participants
Start Date
April 16, 2012
Primary Completion Date
March 29, 2018
Study Completion Date
March 29, 2018
Alisertib
Given PO
Laboratory Biomarker Analysis
Correlative studies
Pharmacological Study
Correlative studies
Vorinostat
Given PO
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
USC / Norris Comprehensive Cancer Center, Los Angeles
City of Hope Comprehensive Cancer Center, Duarte
University of California Davis Comprehensive Cancer Center, Sacramento
Penn State Milton S Hershey Medical Center, Hershey
National Cancer Institute (NCI)
NIH